<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983658</url>
  </required_header>
  <id_info>
    <org_study_id>OXF4696g</org_study_id>
    <nct_id>NCT00983658</nct_id>
  </id_info>
  <brief_title>A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma</brief_title>
  <official_title>A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed&#xD;
      to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by&#xD;
      IV infusion for the treatment of allergen-induced asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the late asthmatic response (LAR) in patients treated with huMAb OX40L versus placebo</measure>
    <time_frame>16 weeks after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LAR after the allergen challenge in patients treated with huMAb OX40L versus placebo</measure>
    <time_frame>Approximately Day 56 prior to third dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in methacholine challenge response relative to the pre-allergen challenge PC20</measure>
    <time_frame>24 hours after each allergen challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early asthmatic response (EAR) in patients treated with huMAb OX40L versus placebo</measure>
    <time_frame>Between 0 and 2 hours after each allergen challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and nature of treatment-emergent adverse events</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and nature of infusion reactions</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious complications</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature, relatedness, and severity of adverse events</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs, electrocardiograms, FEV1, and safety laboratory measures</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>huMAb OX40L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>huMAb OX40L</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>huMAb OX40L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Weight between 50 and 125 kg&#xD;
&#xD;
          -  Mild, stable allergic asthma&#xD;
&#xD;
          -  History of episodic wheeze and shortness of breath&#xD;
&#xD;
          -  FEV1 at baseline ≥ 70% of the predicted value&#xD;
&#xD;
          -  For women of childbearing potential, agreement to use an effective means of&#xD;
             contraception while enrolled in the study&#xD;
&#xD;
          -  For men with partners of childbearing potential, willingness to use condoms with&#xD;
             spermicide during treatment&#xD;
&#xD;
          -  Ability to comprehend and follow all required study procedures&#xD;
&#xD;
          -  Positive skin prick test to common aeroallergens (e.g., cat, dust, mite, grass, and&#xD;
             pollen)&#xD;
&#xD;
          -  Positive allergen-induced early and late airway bronchoconstriction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A worsening of asthma or a respiratory tract infection within 6 weeks preceding study&#xD;
             entry&#xD;
&#xD;
          -  Acute infection (including viral infection) within the 6 weeks preceding dosing (8&#xD;
             weeks for respiratory infections) or any ongoing chronic infection&#xD;
&#xD;
          -  History of recurrent bacterial infection as an adult or history or presence of any&#xD;
             chronic infectious condition, including (but not limited to), tuberculosis, parasitic&#xD;
             infection, etc.&#xD;
&#xD;
          -  Lung disease other than mild allergic asthma&#xD;
&#xD;
          -  History of heart, lung, kidney, liver, neurologic or chronic infectious disease&#xD;
&#xD;
          -  Concomitant disease or condition, which could interfere with the conduct of the study,&#xD;
             including, but not limited to, cancer, alcoholism, drug dependency or abuse, or&#xD;
             psychiatric disease&#xD;
&#xD;
          -  History of serious adverse reaction or hypersensitivity to any drug&#xD;
&#xD;
          -  Pregnancy or lactation or positive serum pregnancy test at screening&#xD;
&#xD;
          -  Chronic use of any other medication for treatment of allergic lung disease other than&#xD;
             short-acting β2-agonists or ipratropium bromide&#xD;
&#xD;
          -  Current (or history of) treatment with a monoclonal antibody or chimeric biomolecule&#xD;
             within the past 5 months (5 half-lives of the drug), including omalizumab&#xD;
&#xD;
          -  Regular use of tobacco products of any kind or within the previous 6 months, or&#xD;
             smoking history &gt; 10 pack-years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana McClintock, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-OX40L</keyword>
  <keyword>Mild Allergic Asthma</keyword>
  <keyword>Allergies</keyword>
  <keyword>Allergic Asthma</keyword>
  <keyword>Adult Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Airway Obstruction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

